ARCHIVES

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

This article is from The Cancer Letter archive.

Vol. 36 No. 44 | December 3, 2010

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

IOM Says “Immediate Steps” Needed To Avert “Crisis” In Cancer Centers Program Funding

April 28, 1989

NCI Names Brawly Director of Office of Special Populations

June 21, 1996

Avon Awards $30M To 13 Organizations

September 27, 2002

NIH Financial Plan Slated For Discussion At Dec. 18 Meeting

December 14, 1990

In Brief: NCI Scientist Accused Of Taking ‘Payoffs’ Forom Drug Firms; GM-CS Wins FDA Approval

March 15, 1991